secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-038757
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q2 net loss $75M, cash $1.0B; deprioritizes etrumadenant in mCRPC
-----------------------------------------------------------------------

- Cash $1.0B vs $1.1B at Dec 2022; 2023 cash burn guided $290-325M; funding into 2026.
- Q2 net loss $75M vs $67M YoY; revenue $29M vs $27M; R&D expenses $84M vs $70M.
- Domvanalimab ARC-7 data: 33% PFS risk reduction for doublet vs PD-1 monotherapy at ~18-mo follow-up.
- Etrumadenant in mCRPC deprioritized; ARC-6 analysis shows insufficient clinical benefit to warrant further investment.
- Gilead collaboration expanded to inflammation; Arcus gets $35M upfront; Gilead bought 1M shares at $19.26, raising stake to 19.9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023038757/0000950170-23-038757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023038757/rcus-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer